EMA’s CHMP Is Set To Adopt Position On Another Avastin Biosimilar
Two EC Approvals, One Positive Opinion So Far
The market for biosimilar Avastin is set to form imminently, with two players holding final approvals from the European Commission waiting in the wings. In the coming days, the EMA’s Committee for Medicinal Products for Human Use is likely to issue an opinion on a further application.
You may also be interested in...
Centus Biotherapeutics has received formal European Commission approval for its Equidacent biosimilar rival to Avastin.
Second-quarter earnings results from two of the Big Three – Teva and Mylan – hold much of the intrigue in August, while more competition in the nascent Avastin biosimilar market could materialize in Europe.
Roche’s biggest seller, Avastin, has fallen to biosimilar competition in Europe, with at least one company confirming launch to Generics Bulletin.